Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes

Fig. 3

Proportions of patients whose biomarker values returned to normal reference ranges at week 24. Proportions of patients with biomarker serum concentrations exceeding the reference range at baseline that normalized to within reference range at week 24. ***Nominal p < 0.0001 vs. adalimumab (X2 test). CRP, C-reactive protein; Lp(a), lipoprotein (a); OC, osteocalcin; OPG, osteoprotegerin; P1NP, procollagen type 1 N-terminal propeptide; q2w, every 2 weeks; RANKL, receptor activator of nuclear factor-κB ligand; SAA, serum amyloid A

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us